President Donald Trump has — moved forward with an executive order directing federal agencies to expedite and complete the rescheduling of cannabis under the federal Controlled Substances Act (CSA), shifting it from a Schedule I drug (highest restriction) to Schedule III (lower restriction more akin to prescription painkillers). This action reflects a major loosening of long‑standing federal cannabis policy and would be the most significant federal reform in decades.
What the Change Means in Practice
- Rescheduling to Schedule III would officially recognize cannabis as having accepted medical use with a lower potential for abuse, easing barriers to research and product development.
- Cannabis would remain federally illegal for recreational use — only reclassification, not decriminalization or full legalization.
- Medical research would be significantly simplified, as Schedule III status removes some of the toughest restrictions on clinical studies.
- Tax relief could materialize for cannabis businesses, which are currently hindered by IRS code Section 280E due to Schedule I status (business expense deductions are disallowed).
The executive order is also expected to include ancillary provisions which expand access to hemp and cannabidiol (CBD) products, including Medicare eligibility for some CBD prescriptions and steps to support the hemp industry and ease federal oversight.
Cannabis stocks responded positively ahead of the announcement, with notable gains in multiple publicly traded companies as investors priced in expectations for lighter federal restrictions.
In related federal news, the U.S. Supreme Court declined to hear a case challenging federal marijuana prohibition, leaving the current legal framework intact for now. This makes executive action — such as rescheduling — one of the few remaining high‑profile avenues for reform at the federal level.
Commentators note the move still falls short of full legalization, pointing out unresolved issues such as continued federal prohibition, regulatory controls and public health concerns. Some critics argue this rescheduling benefits corporate interests more than public health or equitable reform.
